A/Prof Shom Goel
Principal Research Fellow
The Sir Peter MacCallum Department of Oncology
141 Scholarly works
12 Projects
HIGHLIGHTS
2026
Journal article
Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer
DOI: 10.1038/s41523-026-00913-42026
Journal article
Single-cell transcriptomics reveals immune landscape dynamics in metastatic hormone receptor-positive breast cancer treated with abemaciclib and endocrine therapy.
DOI: 10.1158/1078-0432.CCR-25-09462026
Journal article
Abstract GS3-06: Rb Functions as a Transcriptional Activator of ER Targets Following CDK4/6 Inhibition in Luminal Breast Cancer
DOI: 10.1158/1557-3265.sabcs25-gs3-062026
Journal article
Abstract RF4-01: Central Nervous System Outcomes from the Phase III PATINA Trial (AFT-38)
DOI: 10.1158/1557-3265.sabcs25-rf4-012025
Research grants (international)
FDP Reciprocal Data Transfer and Use Agreement With DFCI- Targeting Senescent Cells to Improve Outcomes for Breast Cancer Patients
2025
Research grants (ARC, NHMRC, MRFF)
Harnessing the Next Generation of Liquid Biopsy Assays for Clinical Translation in Breast Cancer
2022
Research grants (other domestic)
Understanding and Targeting Therapy-Induced Senescence in Cancer
RECENT SCHOLARLY WORKS
2026
Journal article
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer
DOI: 10.1056/NEJMoa25112182026
Journal article
CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors
DOI: 10.1016/j.ymthe.2026.03.0242025
Journal article
Correction: INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors(Cancer Discov 2024, 14,446–67.)
DOI: 10.1158/2159-8290.CD-25-15022025
Journal article
422TiP Randomized phase 2 trial of preoperative atirmociclib plus letrozole on Ki-67 tumor expression in HR /HER2− early breast cancer
DOI: 10.1016/j.annonc.2025.08.8462025
Journal article
485MO Health-related quality of life (HRQoL) from the PATINA trial (AFT-38): Impact of adding palbociclib to HER2 and endocrine therapy (ET) after induction in HR /HER2 metastatic breast cancer (MBC)
DOI: 10.1016/j.annonc.2025.08.9092025
Journal article
624TiP Randomized phase 3 clinical trial evaluating atirmociclib plus letrozole versus a CDK4/6 inhibitor plus letrozole as first-line treatment for patients with HR /HER2− advanced/metastatic breast cancer
DOI: 10.1016/j.annonc.2025.08.1046
RECENT PROJECTS
2024
Research grants (international)
Enhancing the Benefits of CDK Inhibition in Breast Cancer
2022
Research grants (international)
Understanding and Targeting Therapy-Induced Senescence in Cancer